Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men

What Was Tested

The paper reports a study of Peptide YY, published as a randomized controlled trial.

Their aim was to examine the effects of GLP-1 and PYY3-36, separately and in combination, on energy intake, energy expenditure, appetite sensations, glucose and fat metabolism, ghrelin, and vital signs in healthy overweight men.

Why It Was Studied

Twenty-five healthy male subjects participated in this randomized, double-blinded, placebo-controlled, four-arm crossover study (BMI 29 ± 3 kg/m(2), age 33 ± 9 yr).

Measurements of appetite sensations, energy expenditure and fat oxidation, vital signs, and blood variables were collected throughout the infusion period.

Who Took Part

By PubMed's age tags, the people studied were teenagers, adults and middle-aged adults, men only.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

Because people in this Peptide YY study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Peptide YY.

Some participants received a placebo instead of Peptide YY, giving a reference point.

In the crossover set-up each of the participants took both Peptide YY and the comparison in turn, acting as their own control.

Ad libitum energy intake was assessed during the final 30 min.

What Was Measured

Measurements of appetite sensations, energy expenditure and fat oxidation, vital signs, and blood variables were collected throughout the infusion period.

Topics PubMed links to this paper include Anthropometry, Appetite, Blood Glucose, Energy Intake, Energy Metabolism, Fatty Acids, Nonesterified and Food Preferences.

Author keywords: GLP-1, PYY and energy expenditure.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Peptide YY.

The publication is from 2014 (American journal of physiology. Endocrinology and metabolism), a journal based in United States.

More context: the Peptide YY compound page, all human trials.